ABT-737 synergizes with Bortezomib to kill melanoma cells

Biology Open

Volumn 1, Issue 2, 2012, Pages 92-100

  Reuland, Steven N ^a   Goldstein, Nathaniel B ^a   Partyka, Katie A ^a   Smith, Shilo ^a   Luo, Yuchun ^a   Fujita, Mayumi ^a   Gonzalez, Rene ^a   Lewis, Karl ^a   Norris, David A ^a,b   Shellman, Yiqun G ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

ABT 737; Bcl 2 inhibitor; Bortezomib; Mcl 1; Melanoma; Noxa; Proteasome inhibitor

Indexed keywords

EID: 84964575129     PISSN: None     EISSN: 20466390     Source Type: Journal    
DOI: 10.1242/bio.2011035     Document Type: Article

References (51)

1. Adams, J., and Kauffman, M. (2004). Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304-311.
2. Adams, J. M., Huang, D. C., Strasser, A.,Willis, S., Chen, L.,Wei, A., van Delft, M., Fletcher, J. I., Puthalakath, H., Kuroda, J., et al. (2005). Subversion of the Bcl-2 life/death switch in cancer development and therapy. Cold Spring Harb. Symp. Quant. Biol. 70, 469-477.
3. Boisvert-Adamo, K., and Aplin, A. E. (2008). Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene. 27, 3301-3312.
4. Buzaid, A. C. (2004). Management of metastatic cutaneous melanoma. Oncology (Williston Park) 18, 1443-1450; discussion 1457-1449.
5. Cartlidge, R. A., Thomas, G. R., Cagnol, S., Jong, K. A., Molton, S. A., Finch, A. J., and McMahon, M. (2008). Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res. 21, 534-544.
6. Certo, M., Del Gaizo Moore, V., Nishino, M., Wei, G., Korsmeyer, S., Armstrong, S. A., and Letai, A. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351-365.
7. Chauhan, D., Velankar, M., Brahmandam, M., Hideshima, T., Podar, K., Richardson, P., Schlossman, R., Ghobrial, I., Raje, N., Munshi, N., et al. (2007). A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26, 2374-2380.
8. Chen, D., Frezza, M., Schmitt, S., Kanwar, J., and Dou, Q. P. (2011). Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 11, 239-253.
9. Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., and Huang, D. C. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403.
10. Chen, S., Dai, Y., Harada, H., Dent, P., and Grant, S. (2007). Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67, 782-791.
11. Chudnovsky, Y., Khavari, P. A., and Adams, A. E. (2005). Melanoma genetics and the development of rational therapeutics. J Clin Invest 115, 813-824.
12. Cummins, D. L., Cummins, J. M., Pantle, H., Silverman, M. A., Leonard, A. L., and Chanmugam, A. (2006). Cutaneous malignant melanoma. Mayo Clin Proc 81, 500-507.
13. Eggermont, A. M. (2010). Advances in systemic treatment of melanoma. Ann Oncol 21 Suppl 7:, vii339-vii344.
14. Gogas, H. J., Kirkwood, J. M., and Sondak, V. K. (2007). Chemotherapy for metastatic melanoma: time for a change? Cancer 109, 455-464.
15. Goldstein, N. B., Johannes, W. U., Gadeliya, A. V., Green, M. R., Fujita, M., Norris, D. A., and Shellman, Y. G. (2008). Active N-Ras and B-Raf Inhibit Anoikis by Downregulating Bim Expression in Melanocytic Cells. J Invest Dermatol. 129, 432-437.
16. Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851-857.
17. Harrison, L. R., Micha, D., Brandenburg, M., Simpson, K. L., Morrow, C. J., Denneny, O., Hodgkinson, C., Yunus, Z., Dempsey, C., Roberts, D., et al. (2011). Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. J Clin Invest. 121, 1075-1087.
18. Hendrickson, A. W., Meng, X. W., and Kaufmann, S. H. (2008). Anticancer therapy: boosting the bang of Bim. J Clin Invest 118, 3582-3584.
19. Kang, M. H., and Reynolds, C. P. (2009). Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15, 1126-1132.
20. Kang, M. H., Kang, Y. H., Szymanska, B., Wilczynska-Kalak, U., Sheard, M. A., Harned, T., Lock, R. B., and Reynolds, C. P. (2007). Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood. 110, 2057-2066.
21. Kline, M. P., Rajkumar, S. V., Timm, M. M., Kimlinger, T. K., Haug, J. L., Lust, J. A., Greipp, P. R., and Kumar, S. (2007). ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 21, 1549-1560.
22. Kohl, T. M., Hellinger, C., Ahmed, F., Buske, C., Hiddemann, W., Bohlander, S. K., and Spiekermann, K. (2007). BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia. 21, 1763-1772.
23. Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y. X., Sneed, T., et al. (2006). Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375-388.
24. Kuhn, D. J., Orlowski, R. Z., and Bjorklund, C. C. (2011). Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs). Curr Cancer Drug Targets 11, 285-295.
25. Labi, V., Grespi, F., Baumgartner, F., and Villunger, A. (2008). Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ 15, 977-987.
26. Letai, A. (2005). BCL-2: found bound and drugged! Trends Mol Med 11, 442-444.
27. Letai, A. (2006). Restoring cancer's death sentence. Cancer Cell 10, 343-345.
28. Lin, X., Morgan-Lappe, S., Huang, X., Li, L., Zakula, D. M., Vernetti, L. A., Fesik, S. W., and Shen, Y. (2006). 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. Oncogene. 26, 3972-3979.
29. Miller, A. J., and Mihm, M. C., Jr. (2006). Melanoma. N. Engl. J. Med. 355, 51-65.
30. Miller, L. A., Goldstein, N. B., Johannes, W. U., Walton, C. H., Fujita, M., Norris, D. A., and Shellman, Y. G. (2009). BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J. Invest. Dermatol. 129, 964-971.
31. Natarajan, N., Telang, S., Miller, D., and Chesney, J. (2011). Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma. Drugs 71, 1233-1250.
32. Olberding, K. E., Wang, X., Zhu, Y., Pan, J., Rai, S. N., and Li, C. (2010). Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. Cancer Biol. Ther. 10, 918-929.
33. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko,M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.
34. Orlowski, R. Z., and Kuhn, D. J. (2008). Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin. Cancer Res. 14, 1649-1657.
35. Paoluzzi, L., Gonen, M., Bhagat, G., Furman, R. R., Gardner, J. R., Scotto, L., Gueorguiev, V. D., Heaney, M. L., Manova, K., and O'Connor, O. A. (2008). The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 112, 2906-2916.
36. Podar, K., Gouill, S. L., Zhang, J., Opferman, J. T., Zorn, E., Tai, Y. T., Hideshima, T., Amiot, M., Chauhan, D., Harousseau, J. L., et al. (2008). A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene 27, 721-731.
37. Qin, J. Z., Xin, H., Sitailo, L. A., Denning, M. F., and Nickoloff, B. J. (2006). Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res. 66, 9636-9645.
38. Qin, J. Z., Ziffra, J., Stennett, L., Bodner, B., Bonish, B. K., Chaturvedi, V., Bennett, F., Pollock, P. M., Trent, J. M., Hendrix, M. J., et al. (2005). Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 65, 6282-6293.
39. Reynoso, D., Nolden, L. K., Yang, D., Dumont, S. N., Conley, A. P., Dumont, A. G., Zhou, K., Duensing, A., and Trent, J. C. (2010). Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol. Oncol. 5, 93-104.
40. Ruth, M. C., Xu, Y., Maxwell, I. H., Ahn, N. G., Norris, D. A., and Shellman, Y. G. (2006). RhoC promotes human melanoma invasion in a PI3K/Akt-dependent pathway. J. Invest. Dermatol. 126, 862-868.
41. Shellman, Y. G., Ribble, D., Miller, L., Gendall, J., Vanbuskirk, K., Kelly, D., Norris, D. A., and Dellavalle, R. P. (2005). Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res. 15, 83-89.
42. Shoemaker, A. R., Oleksijew, A., Bauch, J., Belli, B. A., Borre, T., Bruncko, M., Deckwirth, T., Frost, D. J., Jarvis, K., Joseph, M. K., et al. (2006). A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs in vitro and in vivo. Cancer Res. 66, 8731-8739.
43. Smith, A. J., Dai, H., Correia, C., Takahashi, R., Lee, S. H., Schmitz, I., and Kaufmann, S. H. (2011). Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. J. Biol. Chem. 286, 17682-17692.
44. Song, J. H., Kandasamy, K., Zemskova, M., Lin, Y. W., and Kraft, A. S. (2010). The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res. 71, 506-515.
45. Tahir, S. K., Yang, X., Anderson, M. G., Morgan-Lappe, S. E., Sarthy, A. V., Chen, J., Warner, R. B., Ng, S. C., Fesik, S. W., Elmore, S. W., et al. (2007). Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 67, 1176-1183.
46. Thomadaki, H., Scorilas, A., and Hindmarsh, J. T. (2006). BCL2 family of apoptosisrelated genes: functions and clinical implications in cancer. Crit. Rev. Clin. Lab. Sci. 43, 1-67.
47. van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006). The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389-399.
48. Wang, Y. F., Jiang, C. C., Kiejda, K. A., Gillespie, S., Zhang, X. D., and Hersey, P. (2007). Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin. Cancer Res. 13, 4934-4942.
49. Weinstein, I. B., and Joe, A. K. (2006). Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3, 448-457.
50. Willis, S. N., Chen, L., Dewson, G., Wei, A., Naik, E., Fletcher, J. I., Adams, J. M., and Huang, D. C. (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19, 1294-1305.
51. Wolter, K. G., Verhaegen, M., Fernandez, Y., Nikolovska-Coleska, Z., Riblett, M., de la Vega, C. M., Wang, S., and Soengas, M. S. (2007). Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ. 14, 1605-1616.